MetaVia
MTVA1.4400.70% ( +0.010 )
MetaVia (MTVA)
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-124...
- Open
- 1.423
- High
- 1.490
- Low
- 1.410
- Prev. Close
- 1.430
- Volume
- 54.81K
- Turnover
- 78.70K
- Avg Price
- 1.436
- Bid/Ask Ratio
- --
- Amplitude
- 5.59%
- 52wk High
- 19.029
- Volume Ratio
- 0.44
- Turnover Ratio
- 1.65%
MetaVia Analyst Rating
View MoreForecast & Rating
Jul 10, 2026Price forecast
$19.331242.59%
Forecast & RatingBuy
2analysts
- Strong buy50.00%
- Buy50.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · Jul 22 at 04:18 AM
A Market Frankenstein: What AI Gambles and Egg Farms Tell Us About Wall Street's Leftovers
- Tip Ranks · Jul 10 at 09:45 AM
Analyst Maintains Buy on MetaVia, Keeps $8 Price Target as DA-1726 Next-Gen Obesity Data Advances
- Tip Ranks · Jul 9 at 07:57 AM
MetaVia Advances DA-1726 Obesity Trial to Top Doses
- PUBT · Jul 9 at 07:33 AM
MetaVia says all active patients reach highest target doses in DA-1726 obesity Phase 1 Part 3 study
- Unusual Whales · Jun 17 at 07:33 AM
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
- Tip Ranks · Jun 12 at 02:55 PM
MetaVia: Buy Rating Reiterated as Synergistic Cardiometabolic Pipeline Supports Unchanged $8 Price Target
